Navigation Links
Tendril SDX Model 1688TC

ProductsTendril SDX Model 1688TC
Company St. Jude Medical, Inc.
Item Tendril SDX Model 1688TC
Features 
  • Steroid elution
  • TiN-coated electrodes
  • Silicone insulation
  • Fast-Pass coating
  • TC models use a standard clip-on tool
Description The Tendril SDX model 1688 and model 1488 active-fixation leads are among the world's thinnest extendable/retractable pacing leads, offering the unsurpassed handling advantages, performance, and reliability evident in St. Jude Medical's line of active-fixation leads. Implantable with a 7 F introducer, the reduced body diameter of the Tendril SDX lead is designed to lower the incidence of venous obstruction and allow introduction in smaller, more tortuous venous pathways.
Info St. Jude Medical, Inc.
Customer Service: (800) 328-9634
Web site: http://www.sjm.com

Related medicine products :

1. Tendril DX Model 1388 T/TC
2. Tendril DX
3. Tendril DX Model 1388 K
4. Tendril SDX Model 1488TC
5. Tendril SDX
6. Tendril SDX Model 1488K
7. Tendril SDX Model 1688T
8. Tendril SDX Model 1488T
9. Tendril™ ST Pacing Lead
10. Reliance Stool, Model 5346
11. Reliance Stools, Model 5340
The incorporation of a reverse osmosis (RO) system and an ultrapure water system into a single stand-alone tower provides numerous benefits to the busy laboratory.
...gy systems produce ultrapure water from pre-treate... the basic needs of scientific laboratories. The S...V lamp (185 nm and 254 nm) to produce water with l...n fed by Elix water). Water quality is easily moni...
...tability and durability. Back-lighted Display. Dig...iple units of measure, piece counting and percent ...put including date and time data from built-in clo...ass for convenient Touch-key calibration. Also ca...
...tability and durability. Back-lighted Display. Dig...iple units of measure, piece counting and percent ...put including date and time data from built-in clo...ass for convenient Touch-key calibration. Also ca...
Medicine Products:
(Date:12/3/2008)...Than Entire U.S. Economy , , DALLAS, Dec. 3...ent stopped the Medicare and Social Security progr...nd allowing no more accrual of benefits -- it woul...lready earned these benefits, according to a new s...CPA). , , "The numbers are staggering," s...
(Date:12/3/2008)...ecific Gamma Imaging (BSGI) has,equivalent sensit...tients with,inconclusive findings after mammograp...er, according to findings presented today at the a...h America (RSNA). BSGI is a molecular breast,imag...raphy that can identify,lesions independent of ti...
(Date:12/3/2008)...e-FirstCall/ -- ThermoGenesis,Corp. (Nasdaq: KO...d services,that process and store adult stem cell... on Thursday, December 4, to discuss its announcem...any. , The conference call will begin at 5:...n Standard Time). The call can be accessed by call...
(Date:12/3/2008)...ed by maintenance treatment, study shows , ...ance therapy using low-dose peginterferon doesn,t ...o haven,t responded to an initial round of treatme...wed a surprising health decline in patients with l...This course of treatment had been adopted by a num...
Breaking Medicine News(10 mins):Health News:Medicare, Social Security Owe Up to $52 Trillion to Current Retirees and Workers 2Health News:Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer 2Health News:ThermoGenesis Corp. Schedules Conference Call/Webcast to Discuss Management Transition 2Health News:Hepatitis C Therapy Useless for Some 2
...year under house arrest for having unprotected sex...ed guilty to aggravated sexual assault, will serve...ts at a Canadian Forces base shook the military, i...oundland to serve her sentence. Justice Michele ...
...cancer patients Chemotherapy Wrong. Blasting wome...the best way to save their lives.// The bigger the...umped into the veins of women to kill it. But this...ea change in 2004. According to guidelines recentl...
...ed cases of avian flu in domestic birds in Buzau c...irus was first isolated in October.// Romanian o...ltry in a village of Padina showed presence of bir... been confirmed as the highly pathogenic H5N1 stra...
...the top among nuts and seeds that contain the high...s cholesterol levels and improves heart health, ac...hnic Institute and State University analysed some ...eved to be the most comprehensive analysis to date...
Other Medicine News:Health News:Fewer Breast Cancer Patients to Get Chemo 2Health News:Fewer Breast Cancer Patients to Get Chemo 3
(Date:12/2/2008)...reyPines Therapeutics, Inc. (Nasdaq: TPTX ) toda...se II trial evaluating three doses of NGX267 as a ...s with Sjogren,s syndrome. NGX267 met the primary...in salivary flow production compared to placebo at...oses were safe and well tolerated with few reports...
(Date:12/1/2008).../ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) ...rld,s leading medical journals, results of clinica...ental compound tasimelteon (VEC-162). The publica... agonist tasimelteon (VEC-162) for transient insom...led multicentre trials." Results are reported from...
(Date:12/1/2008)...-way switch that, if turned off, causes lymphatic ...lose their identity and become more like blood end...PRNewswire-USNewswire/ -- Scientists at St. Jude ...a certain differentiated cell type is so ready to ...expression of a gene called Prox1 to dissuade it...
(Date:12/1/2008)...oVax Labs, Inc.,(OTC Bulletin Board: GOVX), an At...n vaccines for diseases caused by HIV-1 (Human Imm... announced today that the launch of its Phase 2a H...es across North and South America.,These trials a...stitutes of,Health (NIH), and the HIV Vaccine Tri...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Moderate Aerobics May Ease Insomnia Symptoms 21763 1Trust for Americas Health Releases Report on Connection between Womens Health and Stalled Infant Mortality Rates 21759 1Trust for Americas Health Releases Report on Connection between Womens Health and Stalled Infant Mortality Rates 21759 2Trust for Americas Health Releases Report on Connection between Womens Health and Stalled Infant Mortality Rates 21759 3Speaker Training 3A Driving Program Impact 26 Influence 21755 1Dental Services Expand to Serve More Than 280 000 Michigan Children 21751 1Dental Services Expand to Serve More Than 280 000 Michigan Children 21751 2
...e for Second Pivotal Phase 3 Trial CL-05, CHICAGO,...Life,Sciences Holdings, Inc. , today announced the...rial CL-06, the first of two,pivotal Phase 3 clini...tiveness of cethromycin, a novel once-a-day antibi...monia (CAP). The Company,also provided an update t...
...007 -- Ablynx today announced positive,interim res...velopment programme, ALX-0081, an anti-thrombotic ...ss´ therapeutic,Nanobody® targeting von ... of thrombosis in patients with acute coronary,syn...s designed to assess,safety, tolerability and phar...
Other Medicine Technology:Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 2Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 3Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 4Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 5Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 7Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2